After simultaneous administration of medroxyprogesterone acetate (MAP) 1,000 mg PO and 1,000 mg IM to ten cancer patients, we observed mean plasma MAP profiles that could be exactly superimposed on the two absorption/decay curves obtained after administration of single doses IM or PO. Treatment with MAP given simultaneously by the IM and PO routes may be effective in overcoming the drawbacks of both routes, and can also more reliably guarantee plasma levels in the therapeutic range.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Nie NH, Hull CH, Jenkins JG, Steinbrenner K, Bent DH (1980) SPSS Statistical package for the social sciences, 2e. éd. McGraw-Hill, New York
Pannuti F, Martoni A, Fruet F, Strocchi E, Di Marco AR (1979) Hormone therapy in advanced breast cancer: High-dose medroxyprogesterone acetate (MAP) vs tamoxifen (TMX). Preliminary results. In: Mouridsen HT, Palshof T (eds) Breast cancer. Experimental and clinical aspects. Pergamon press, London, pp 93–98
Pannuti F, Camaggi CM, Strocchi E, Giovannini M, Di Marco AR, Costanti B (1981) Medroxyprogesterone acetate (MAP): Relative bioavailability after single high-dose administration in cancer patients. Cancer Treat Rep
About this article
Cite this article
Pannuti, F., Camaggi, C.M., Strocchi, E. et al. Medroxyprogesterone acetate (MAP) plasma levels after simultaneous oral and intramuscular administration in cancer patients. Cancer Chemother. Pharmacol. 9, 122–123 (1982). https://doi.org/10.1007/BF00265393
- Cancer Patient
- Cancer Research
- Plasma Level
- Single Dose